| Accession Number: | 0001209191-21-031376 |
| Date: | 2021-05-06 |
| Issuer: | ULTRAGENYX PHARMACEUTICAL INC. (RARE) |
| Original Submission Date: |
BEDROSIAN CAMILLE L
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO, CA 94949
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2021-05-06 | S | 364 | d | $113.67 | 38,775 | direct |
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|
| ID | footnote |
|---|---|
| f1 | represents shares sold to pay required tax withholdings due to the vesting of rsus. |
| f2 | includes previously reported shares of common stock underlying rsus granted to the reporting person, which are subject to certain vesting conditions. |
